➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Medtronic
AstraZeneca
Dow
Colorcon

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CUBICIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Cubicin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00295178 ↗ Study Comparing CUBICINĀ® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed Cubist Pharmaceuticals LLC Phase 4 2006-02-01 This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: - Time to erythema margin cessation to progress - Time to defervescence - Time to hospital discharge following relief of the presenting cellulitis or erysipelas - Degree of improvement of the following signs and symptom of cellulitis or erysipelas including - Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
NCT00638157 ↗ Phase 4 Efficacy and Safety Study of CubicinĀ® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) Terminated Cubist Pharmaceuticals LLC Phase 4 2008-03-01 multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
NCT00651131 ↗ Cubicin(R) for Complicated Post-Surgical Wound Infections Terminated Cubist Pharmaceuticals LLC Phase 4 2004-06-01 The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cubicin

Condition Name

Condition Name for Cubicin
Intervention Trials
Wound Infections 1
Diabetic Foot Infection 1
Meningitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cubicin
Intervention Trials
Infection 3
Communicable Diseases 3
Erysipelas 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cubicin

Trials by Country

Trials by Country for Cubicin
Location Trials
United States 10
China 9
France 1
Switzerland 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cubicin
Location Trials
Pennsylvania 2
Michigan 2
Texas 2
Minnesota 1
Oklahoma 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cubicin

Clinical Trial Phase

Clinical Trial Phase for Cubicin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cubicin
Clinical Trial Phase Trials
Completed 4
Terminated 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cubicin

Sponsor Name

Sponsor Name for Cubicin
Sponsor Trials
Cubist Pharmaceuticals LLC 5
AstraZeneca 1
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cubicin
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Express Scripts
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.